Citations
Economic analysis of trastuzumab in Colombia.
Análisis económico del trastuzumab en Colombia.
Open | Download
How to Cite
1.
Carranza H, Vargas C, Bernal L, Otero JM, Cardona AF. Economic analysis of trastuzumab in Colombia. Rev. colomb. hematol. oncol. [Internet]. 2013 Jul. 1 [cited 2025 Dec. 5];2(2):12-4. https://doi.org/10.51643/22562915.339
Download Citation
Section
Editorial
How to Cite
1.
Carranza H, Vargas C, Bernal L, Otero JM, Cardona AF. Economic analysis of trastuzumab in Colombia. Rev. colomb. hematol. oncol. [Internet]. 2013 Jul. 1 [cited 2025 Dec. 5];2(2):12-4. https://doi.org/10.51643/22562915.339
Dimensions
license
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Show authors biography
Article visits 218 | PDF visits 1275
Downloads
Download data is not yet available.
- Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, et al.; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4 Suppl 3:S1-22; quiz S23-4. DOI: https://doi.org/10.6004/jnccn.2006.2003
- Buendía JA, Vallejos C, Pichón-Rivière A. Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia. Biomédica. 2013;33(3). DOI: https://doi.org/10.7705/biomedica.v33i3.832
- Comisión de Regulación en Salud. Reporte de evaluación de posible inclusión al POS para trastuzumab. Universidad Nacional de Colombia, Facultad de Medicina, Instituto de Investigaciones Clínicas.
- Ministerio de Salud y Protección Social, Colciencias, Centro de Estudios e Investigación en Salud de la Fundación Santa Fe de Bogotá, Escuela de Salud Pública de la Universidad de Harvard. Guía metodológica para el desarrollo de guías de atención integral.
- Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):1-192. DOI: https://doi.org/10.3310/hta8490
- Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409-18. DOI: https://doi.org/10.1111/j.1524-4733.2008.00489.x
- Drummond MF, Sculper MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005. DOI: https://doi.org/10.1093/oso/9780198529446.001.0001
- Chicaíza L, Vega R. Determinantes de la utilización de la evaluación económica en la toma de decisiones dentro del sistema de salud colombiano. Innovar Revista de Ciencias Administrativas y Sociales, Universidad Nacional de Colombia. 2012;18(31):77-9.
- Garau M, Shah KK, Mason AR, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics. 2011;29(8):673-85. DOI: https://doi.org/10.2165/11588250-000000000-00000
- Ferrusi IL, Leighl NB, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? ajmc.com [online] 2011 [cited 2013 Jul 8]. Available from: http://www.ajmc.com/publications/supplement/2011/AJMC_11JOPmay/AJMC_11JOPmay_Ferrusi_SP61to70/4.
- NICE. Appraising life-extending, end of life treatments. 2009. Avalilable from: http://www.nice.org.uk/media/88A/F/supplementaryAdviceTACEoL.pdf.
- BID. Método de la costo-efectividad incremental. 2013. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the NICE cost effectiveness threshold.
- Danese MD, Lalla D, Brammer M, Doan Q, Knopf K. Estimating recurrences prevented from using trastuzumab in HER-2/neupositive adjuvant breast cancer in the United States. Cancer. 2010;116(24):5575-83. DOI: https://doi.org/10.1002/cncr.25347
- National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. NICE technology appraisal guidance 107, 2006.
- Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Costeffectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol. 2007;18(9):1493-9. DOI: https://doi.org/10.1093/annonc/mdm185
- Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011;50(3):344-52. DOI: https://doi.org/10.3109/0284186X.2011.553841
- Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P. Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer. 2012;106(1):32-8. DOI: https://doi.org/10.1038/bjc.2011.506
- Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559-66. DOI: https://doi.org/10.1007/s10549-007-9679-4
- Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12 Suppl 3:S82-4. DOI: https://doi.org/10.1111/j.1524-4733.2009.00634.x
Tutorials
About the journal
Information
Directories and Indexers
Plagiarism Check
Descriptor
Google Scholar profile
QR code
Keywords
Most read in the last 30 days
